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Abstract 
Liposomes are nanoparticles used in drug delivery that distribute over several days in humans and 
larger animals. Radiolabeling with long-lived positron emission tomography (PET) radionuclides, 
such as manganese-52 (52Mn, T½ = 5.6 days), allow the imaging of this biodistribution. We report 
optimized protocols for radiolabeling liposomes with 52Mn, through both remote-loading and 
surface labeling. For comparison, liposomes were also remote-loaded and surface labeled with 
copper-64 (64Cu, T½ = 12.7 hours) through conventional means. The chelator DOTA was used in 
all cases. The in vivo stability of radiometal chelates is widely debated but studies that mimic a 
realistic in vivo setting are lacking. Therefore, we employed these four radiolabeled liposome types 
as platforms to demonstrate a new concept for such in vivo evaluation, here of the chelates 52Mn-
DOTA and 64Cu-DOTA. This was done by comparing “shielded” remote-loaded with “exposed” 
surface labeled variants in a CT26 tumor-bearing mouse model. Remote loading (90 min at 55 oC) 
and surface labeling (55 oC for 2 hours) of 52Mn gave excellent radiolabeling efficiencies of 97-
100% and 98-100% respectively, and the liposome biodistribution was imaged by PET for up to 8 
days. Liposomes with surface-conjugated 52Mn-DOTA exhibited a significantly shorter plasma 
half-life (T½ = 14.4 h) when compared to the remote-loaded counterpart (T½ = 21.3 h), whereas 
surface-conjugated 64Cu-DOTA cleared only slightly faster and non-significantly, when compared 
to remote-loaded (17.2 ± 2.9 h versus 20.3 ± 1.2 h). From our data, we conclude the successful 
remote-loading of liposomes with 52Mn, and furthermore that 52Mn-DOTA may be unstable in vivo 
whereas 64Cu-DOTA appears suitable for quantitative imaging.    
Keywords: Manganese-52, copper-64, liposomes, DOTA, remote-loading, ionophore 
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1. Introduction 
 
The development of optimized drug delivery methods for anticancer therapies remains under 
intense investigation [1]. At the forefront of these efforts is the desire to target cytotoxic chemo- 
and radiotherapeutics directly to cancerous tissue, thereby enhancing efficacy and decreasing dose-
limiting side-effects. Such targeting can be obtained using nanoparticles, as these accumulate in 
solid tumors through the enhanced permeation and retention (EPR) effect [2,3]. Liposomes are 
biocompatible and inexpensive to manufacture, even in large scale, making them arguably the most 
promising and most intensely researched class of nanoparticles. Labeling liposomes with 
radionuclides allows scientists to investigate their in vivo behavior and obtain direct quantitative 
data on biodistribution, drug targeting and clearance. This is an extremely valuable tool in the on-
going research to improve liposomal drug delivery. In addition, radiolabeled liposomes hold 
promise as delivery vehicles for internal radiotherapy, and as theranostic tools, where radiolabeled 
diagnostic liposomes predict the efficacy of their therapeutic counterparts [4]. Accordingly, the 
development and use of radiolabeling techniques for liposomes has become an integral part of the 
nanomedicine field [5–7]. 
 
The in vivo biodistribution of radiolabeled liposomes can be obtained by modern imaging 
techniques, such as positron emission tomography (PET). Since therapeutically relevant long-
circulating liposomes have plasma half-lives of about 10-20 hours in mice, the distribution from the 
blood stream to accumulating organs occurs within 2-3 days in murine models [8]. This makes the 
positron-emitting radionuclide 64Cu (t½ = 12.7 h, Emean = 278 keV) well-suited for preclinical PET 
imaging in small animals. However, the long-term fate and clearance of liposomes occurring after 
the initial 2-3 day distribution phase (“post-distribution”) cannot be quantified using 64Cu. 
Moreover, the plasma half-life of liposomes is extended in larger animals, being about 30-90 hours 
in humans [9]. Therefore, comprehensive PET studies of liposomes in animal models beyond 
rodents also require longer-lived radionuclides. As recent technological advances have made the use 
of the PET radionuclides zirconium-89 (89Zr, t½ = 3.3 days) and iodine-124 (124I, t½ = 4.2 days) 
feasible, these have garnered widespread interest in preclinical PET imaging, especially for 
antibody imaging in the case of Zr-89 [10–12]. However, implementation of these radionuclides in 
nanomedicine and in general has been limited due to the challenging radiochemistry of the highly 
oxophilic 89Zr+4 ion, and the cascade gamma photons and in vivo deiodination of 124I, making 
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imaging with these two radionuclides suboptimal. Manganese-52 (52Mn, t½ = 5.6 days) has 
therefore recently gained interest. In addition to its long physical half-life, 52Mn has a high positron 
branch (29.4%) compared to 64Cu (17.9%) and a low positron energy (Emean = 242 keV) which 
gives a short positron-range and high resolution PET images [13]. In addition, the straight-forward 
radiochemistry of 52Mn, allows the use of standard chelators such as EDTA, DTPA and DOTA. 
Further, our and associated groups recently reported procedures for preparing 52Mn in purities high 
enough for use in PET radiotracers such as liposomes [14,15]. Its facile chelation by DOTA was 
also reported, in addition to preliminary evidence for good in vitro and in vivo stability of the Mn-
DOTA chelate. These properties make 52Mn highly useful in preclinical PET imaging, although its 
high gamma dose may discourage use in humans.  
 
Efficient radiolabeling of liposomes can be obtainedachieved in two general ways. Either the 
radionuclide is loaded into the aqueous core of the liposome, known as remote-loading (figure 1). 
Using this technique, 64Cu has been shown to cross the liposomal membrane and be chelated by 
encapsulated DOTA with excellent (>95%) radiolabeling yields [7]. In addition, Edmonds et al. 
recently reported a procedure for remote-loading 52Mn through encapsulated metal-complexing 
drugs [16]. Alternatively, radiometals can be bound by chelators on the liposome surface, a method 
that has also been reported for 64Cu using several different chelators [17,18]. In order to rely on 
results from such surface-labeling (figure 1), the stabilities of the employed chelates must be 
ascertained. Suboptimal stability will result in the release or transchelation of free radiometal with 
biodistributions that differ from the investigated tracer [19,20]. Indeed, the stability of radiometal-
chelator complexes placed on the surface of nanoparticles, on antibodies, peptides or small 
molecules, is paramount for conducting precise quantitative studies. However, the stability of 
radiometal-chelator complexes exposed directly to the bloodstream is still debated. This is 
especially true for the 64Cu-DOTA chelate, one of the most used radiometal radiolabeling strategies 
in both research and the clinic [21–23]. As a result, a general reluctance to employ DOTA in 
imaging studies has been expressed, over concerns of release of the radionuclide from the chelate 
[24]. Due to the widespread use of 64Cu-DOTA, phasing it out would incur significant expenses. 
For this reason, further investigations are highly warranted to clarify if the reported transchelation 
from 64Cu-DOTA is relevant in quantitative imaging. However, sound methodology for studying 
the stability of radiometal chelates under realistic in vivo conditions is currently lacking. With an 
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expected increase in the preclinical use of the 52Mn-DOTA chelate, such studies are also relevant 
for this radionuclide. 
 
In the present study, we report the radiolabeling of liposomes with 52Mn by remote-loading (52Mn-
remote) and surface labeling (52Mn-surface), both optimized for quantitative radiochemical yields. 
In addition, we prepared liposomes remote-loaded (64Cu-remote) and surface-labeled with 64Cu 
(64Cu-surface). All four were prepared as the DOTA chelates, and used to demonstrate a new 
liposome-based concept for the realistic in vivo evaluation of radiometal-chelate stability. By 
preparing remote-loaded liposomes, where the chelate is effectively shielded from the bloodstream, 
and comparing these with surface-labeled chelates that are exposed to the bloodstream, an analysis 
of the biodistribution and plasma excretion can be used to assess chelate stability. In the present 
study, this concept was used to investigate the stability of 64Cu-DOTA and 52Mn-DOTA.    
 
 
 
Figure 1: Radiolabeling of liposomes with 52Mn or 64Cu using surface conjugated or encapsulated 
DOTA chelators. The remote loading of 52Mn is assisted by ionophores that facilitate the transport 
of the radionuclide across the lipid bilayer, where it is trapped by the high affinity chelator DOTA. 
The special membrane permeability of copper allows for heat-induced and ionophore-free 
“unassisted” remote loading of 64Cu into the liposome. Alternatively, the liposome can be surface-
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labeled by 52Mn or 64Cu by direct binding of the radionuclide to DOTA-DSPE lipid conjugates 
present on the membrane surface. 
 
 
Chart 1: Structures of ionophores and the DOTA-DSPE lipid conjugate. 
 
 
2. Materials and methods 
 
2.1 Materials 
All chemicals where purchased from Sigma Aldrich, unless otherwise noted. 1,2-
Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) was purchased from Avanti Polar Lipids. 
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono-N-hydroxysuccinimide ester 
(DOTA-NHS ester) was purchased from Macrocyclics, Inc. Premixed stealth liposome mixture 
(HSPC:Chol:DSPE-PEG2k 565:382:53, molar ratio) was purchased from Lipoid. All chemicals and 
reagents were of analytical grade, obtained from commercial sources and used without further 
purification. Sephadex G-25 PD-10 columns (8.3 mL bed volume) were purchased from GE 
Healthcare. All water was collected from a Milli-Q system (Millipore), unless otherwise noted. 
Ionophores 8-hydroxyquinoline (8-HQ), 2-hydroxyquinoline (2-HQ), 5,7-diiodo-8-
hydroxyquinoline (8-HQ-2I), 5,7-dichloro-8-hydroxyquinoline (8-HQ-2Cl) were purchased from 
Sigma Aldrich (Chart 1). Hiruidin tubes were purchased from Roche, and Zymosan A 
from Saccharomyces cerevisiae, from Sigma Aldrich. The ELISA kit was purchased from Quidel 
and measured on a Victor3 microplate reader (Perkin Elmer). 
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All radio-TLC analyses were performed on silica gel 60 F254 plates (Merck) with 5% 
(w/v) NH4OAc in H2O-MeOH (1:1) as eluent, unless otherwise noted (
52Mn-surface was analyzed 
on cellulose). Quantification of radio traces was achieved on a MiniGita Star using a Beta Detector 
GMC probe (both Raytest), or on a Cyclone Plus Storage Phosphor System (Perkin-Elmer). 
Radioactivity was measured using a Veenstra Instruments dose calibrator VDC-505. Metal content 
of radioactive preparations was quantified with an ICAP 7000 ICP-OES (Thermo Scientific). 
Liposome sizes were measured by dynamic light scattering (DLS) on a ZetaPALS (Brookhaven). 
Liposomes were sized by pressure extrusion using a 10 mL LIPEX thermobarrel pressure extruder 
(20 bar nitrogen pressure) [7]. Lipid concentrations were determined by an iCAPQ ICP-MS 
(Thermo Scientific). 
An isotonic TRIS-saline buffer (ISO-TRIS) containing tris(hydroxymethyl) 
aminomethane (TRIS, 10 mM) and NaCl (150 mM) was prepared and adjusted to pH 7.8 with 
HCl/NaOH (osmolality: 280 mOsm/kg). An isotonic HEPES-saline buffer (ISO-HEPES) containing 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 10 mM) and NaCl (150 mM) was 
prepared by mixing molar equal amounts of sodium HEPES salt and free acid HEPES, for a final 
pH of 7.4-7.5 and osmolality of 292 mOsm/kg. For EDTA challenge, a 1.0 mM EDTA solution in 
ISO-HEPES was used (pH 7.4). 
 
2.2 Preparation of 52Mn and 64Cu 
52Mn was produced by proton irradiation of natural chromium using a PETtrace cyclotron (GE 
Healthcare), following a previously described procedure [15]. In brief, the irradiated chromium was 
dissolved in hydrochloric acid, and the 52Mn was separated by sequential extractions onto a strong 
anion exchange resin (AG1x8, Bio-Rad) from ethanol-HCl mixtures. The purified 52Mn was eluted 
in dilute aq. HCl (0.1 M) for use in the liposome labeling experiments. Samples from the elution 
were analyzed for metal ion content by inductively coupled plasma optical emission spectroscopy 
(ThermoScientific iCAP 6000 Series) in aq. HCl (0.3 M) against dissolved chloride-salt standards 
of Mn, Cr, Co, Fe, and Zn. For metal content in the 52Mn preparations, see Supplementary 
Materials S1. 
64Cu was produced by proton irradiation of an electroplated 64Ni target, and purified 
by anion exchange chromatography in aqueous HCl media. The 64Cu was ultimately obtained in aq. 
HCl (1.0 M), and dried under argon flow for use in radiolabeling, as previously described [25]. 
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2.3 Synthesis of DSPE-DOTA 
DOTA-NHS ester (34 mg, 45 µmol) and DSPE (28 mg, 37 µmol) were dissolved in 
dichloromethane (8 mL). N,N-diisopropylethylamine (140 uL, 0.84 mmol) was added and the 
reaction proceeded overnight at room temperature (RT). The solvent was removed under reduced 
pressure and the product purified by semi-preparative HPLC (Waters 600 Pump & Controller, 
Waters 2489 UV/Visible detector) using a Waters XTerra® C8 5 µm (10x150 mm) column. Eluent: 
(A) 5% acetonitrile + 0.1% trifluoroacetic acid in water, (B) 0.1% trifluoroacetic acid in 
acetonitrile. Gradient profile; linear gradient from 50% B to 100% B over 15 min followed by 5 min 
at 100% B. Flow rate; 5 mL/min. DSPE-DOTA was isolated as a broad peak from 11-18 min. 
Fractions were analysed by MALDI-TOF and those containing the desired product and no 
detectable impurities were pooled. The product was lyophilised to obtain a white powder (21 mg, 
19 µmol, 50% yield, Chart 1). MALDI-TOF MS (positive mode): Calc. M+H+: 1134.8 Da., Obs. 
M+H+: 1134.7 Da. 1H-NMR (400 MHz, chloroform-d:methanol-d, 9:1): δ 5.1 (m, 1H), 4.3 (m, 2H), 
4.1 (m, 2H), 4.0-2.5 (br. m, 28H), 2.2 (m, 4H), 1.4 (m, 4H), 1.2 (m, 56H), 0.8 (m, 6H). For NMR 
spectrum, see Supplementary Materials S2. 
 
2.4 Preparation of liposomes (DOTA1%, LIP405, LIP780) 
For surface loading: A stealth lipid mixture containing 1.0 mol% DSPE-DOTA 
(HSPC:Chol:DSPE-PEG2k:DSPE-DOTA 560:378:52:10, molar ratio) was freeze-dried from tert-
butanol:water (9:1). The obtained lyophilizate was hydrated with an aqueous ISO-HEPES buffer 
(see section 2.1) at 65 oC for 60 min and subsequently sized by pressure extrusion, furnishing 
DOTA1% liposomes. The average liposome size was 102 nm (PDI 0.005) as measured by DLS, and 
the lipid concentration was 27 mM based on measuring the phosphorous content by ICP-MS. For 
remote loading: Liposomes entrapping 10 mM DOTA were prepared with internal pH values of 
4.05 (LIP405) or 7.80 (LIP780). Stealth liposome mixture was hydrated in either a DOTA-HEPES 
buffer (10 mM HEPES, 150 mM NaCl, 10 mM DOTA, pH 4.05, 304 mOsm/kg) or a DOTA-TRIS 
buffer (10 mM TRIS, 150 mM NaCl, 10 mM DOTA, pH 7.80, 299 mOsm/kg), at 65 oC for 60 min. 
Subsequently the liposomes were sized by pressure extrusion. The external medium of the DOTA-
HEPES liposomes was replaced with ISO-HEPES buffer and the external media of the DOTA-
TRIS liposomes with ISO-TRIS using dialysis or tangential flow filtration, as previously described 
[7]. The size and lipid concentration were 99 nm (PDI 0.033) and 63 mM for the DOTA-HEPES 
liposomes and 102 nm (PDI 0.043) and 14.7 mM for the DOTA-TRIS liposomes. 
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2.5 Remote-loading of liposomes with 52Mn and 64Cu (general procedures) 
Loading of 52Mn: To a solution of 52Mn in 0.1 M aq. HCl (4-5 MBq) was added a solution of 
ionophore in ethanol (8HQ, 2HQ, 8HQ-2I or 8HQ-C2l, 128 µL, 50 µM). The mixture was dried in 
HPLC vials at 120 oC under an argon stream (maximum 10 minutes). To the dry mixtures was 
added LIP480 or LIP780 (320 µL, 10 mM lipid) and the reaction mixtures were magnetically stirred 
at 55 oC. At specified time-points (typically 1h, 2h and 3h), the mixtures were analyzed by radio-
TLC and size-exclusion chromatography (SEC). For SEC analysis, an aliquot (80 µL) was mixed 
with a solution of EDTA in ISO-HEPES buffer (1.0 mM EDTA, 80 µL) and allowed to equilibrate 
for 5-10 minutes. Mixtures were then applied to a PD-10 cartridge and eluted with ISO-HEPES. 
Two consecutive fractions of 5.5 mL each were collected and their radioactivity quantified on a 
dose-calibrator. The PD-10 derived encapsulation efficiency was determined as the ratio of the 
radioactivity in the liposome fraction (fraction one, 5.5 mL) to the total radioactivity in fraction one 
and two combined (11 mL). Radio-TLC showed two spots corresponding to 52Mn-DOTA (Rf = 0.3) 
and free unloaded 52Mn (Rf = 0). The TLC derived encapsulation efficiency was determined as the 
ratio of the 52Mn-DOTA activity to the total radioactivity in all peaks combined. After 3 hours, the 
remaining mixture was mixed 1:1 with a solution of EDTA in ISO-HEPES (1.0 mM EDTA) and 
allowed to equilibrate for 24 hours at room temperature (RT). The mixture was then analyzed by 
PD-10 as described above. The loading experiments were conducted at 10 mM lipid, 20 µM 
ionophore and a 52Mn radioactivity concentration of 13 MBq/mL and performed in triplicate. 
Loading of 64Cu: Remote-loading of 64Cu into liposomes was conducted as previously described 
[3,7].  
 
2.6 Ionophore concentration effect on the remote-loading of liposomes with 52Mn  
Ionophore concentrations of 2, 10, 20 and 50 µM were compared. A solution of 52Mn in 0.1 M aq. 
HCl (20 µL, about 930 kBq) was mixed with a 50 µM solution of 8HQ-2Cl in ethanol (2 µM: 8 µL, 
10 µM: 40 µL, 20 µM: 80 µL, 50 µM: 200 µL). The resulting mixtures were dried at 120 oC under a 
stream of argon (2 µM: 1 min, 10 µM: 1.5 min, 20 µM: 2 min, 50 µM: 5 min). The dry 52Mn-
ionophore complex was mixed with TRIS buffer (64 µL) and heated to 55 oC. Then a dispersion of 
LIP780 (14.7 mM lipid, 136 µL) was added for a final lipid concentration of 10 mM and a 52Mn 
radioactivity concentration of 5 MBq/mL. The mixtures were stirred at 55 oC and analyzed by 
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radio-TLC at 1, 8, 15, 30, 60 and 120 minutes. This experiment was done in triplicate (n = 3) for 
each ionophore concentration. 
 
2.7 Surface radiolabeling of liposomes with 52Mn and 64Cu 
Surface labeling of DOTA1% liposomes with 52Mn or 64Cu was conducted at 10 and 20 mM final 
lipid concentrations. Surface-labeling with 52Mn: ISO-HEPES buffer (10 mM lipid: 188 µL, 20 
mM lipid: 70 µL) was mixed with a solution of 52Mn in ISO-HEPES buffer (13.3 µL, 3.9-4.7 MBq). 
To this solution was added a dispersion of DOTA1% liposomes (27 mM lipid concentration) in 
ISO-HEPES (10 mM: 119 µL, 20 mM: 237 µL) for final lipid concentrations of 10 mM or 20 mM. 
These mixtures were heated to 55 oC while stirred magnetically. After 1 h, 2 h and 3 h, the mixtures 
were analyzed by radio-TLC on cellulose (eluted in 100 mM citrate, pH 8.4) and on PD-10 columns 
as described in section 2.5. 52Mn-DOTA-DSPE was shown not to elute on TLC, whereas free 52Mn 
could be quantified as 52Mn-Citrate (Rf = 1.0). Subsequently, a 24 h EDTA challenge study was 
conducted as also described in section 2.5. Surface-labeling with 64Cu: A dispersion of DOTA1% 
liposomes in ISO-HEPES (500 µL, 10 or 20 mM lipid) was added to dry 64CuCl2 (98-106 MBq). 
The resulting mixtures were magnetically stirred at 55 oC. At 1 h, 2 h and 3 h, the reaction mixtures 
were challenged with 1 mM EDTA in ISO-HEPES as described in section 2.5. Radio-TLC and PD-
10 were conducted, followed by a 24 h EDTA challenge as described in section 2.5. 64Cu-DOTA-
DSPE was shown not to elute on TLC, whereas free 64Cu could be quantified as 64Cu-EDTA (Rf = 
0.7). These experiments were done in triplicate (n = 3) for each lipid concentration. 
 
2.8 Preparation of radiolabeled liposomes for in vivo experiments  
All radiolabeled liposome preparations for in vivo use were 20 mM lipid, 2.0 mL and 12.5 MBq/mL 
(52Mn) or 75 MBq/mL (64Cu) at time of injection. 52Mn-remote: A solution of 52Mn in 0.1 M HCl 
(25 MBq, 95 µL) was mixed with a solution of 8HQ-2Cl in ethanol (50 µM 8HQ-2Cl, 1036 µL). 
The mixture was taken to dryness at 120 oC under an argon stream (5 min). A dispersion of LIP780 
(14.7 mM lipid, 1750 µL) was added and the reaction mixture was magnetically stirred at 55 oC for 
90 min. Then, empty liposomes were added to reach a lipid concentration of 20 mM. PD-10 
analysis and radio-TLC were conducted as described above (section 2.5), showing 94% and 99% 
loading efficiency respectively. 52Mn-surface: 25 MBq in 0.1 M HCl (95 µL) was dried at 120 oC 
using argon (5 min). To the dry 52Mn was added ISO-HEPES (520 µL) and the mixture was 
magnetically stirred at 55 oC for 10 min. DOTA1% liposomes (1480 µL, 27 mM lipid) was added 
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and the stirring was continued for 2 h at 55 oC. PD-10 analysis and radio-TLC were conducted as 
described above (section 2.5) showing 99% and 100% loading efficiency respectively. 64Cu-
remote: To a vial containing dry CuCl2 (360 MBq) was added LIP780 liposomes (14.7 mM lipid, 
1750 µL) and the reaction mixture was magnetically stirred at 55 oC for 75 min. Then, empty 
liposomes were added to reach a lipid concentration of 20 mM. PD-10 analysis and radio-TLC were 
conducted as described above (section 2.5) showing 97% and 100% loading efficiency respectively. 
64Cu-surface: To a vial containing dry CuCl2 (360 MBq) was added DOTA1% liposomes (27 mM 
lipid, 1480 µL). The reaction mixture was magnetically stirred at 55 oC for 2 h. Finally, an aliquot 
of the reaction mixture (80 µL) was mixed with 1.0 mM EDTA in ISO-HEPES (80 µL) and after 5-
10 minutes of equilibration, PD-10 and radio-TLC analyses were conducted as described above 
(section 2.5). A loading efficiency of 93% and 100% was observed for PD-10 and TLC 
respectively. The loading efficiency was also analyzed on HPLC-SEC (Sephadex 25G superfine, 
prepacked in a GE Healthcare Tricorn 5/200 column, 0.4 ml/min ISO-TRIS), which showed 98% 
loading efficiency. 
 
2.9 Animal model 
All experimental procedures were approved by, and conducted under the guidelines of The Danish 
Animal Experiments Inspectorate. Immunocompetent Balb/C mice (Charles River Laboratories) 
were inoculated subcutaneously with 3 x 105 CT26 cancer cells (murine colon carcinoma, ATCC, 
Virginia, US) in 100 µL medium in the right flank. Tumor sizes were calculated from the formula 
tumor size = 0.5 · (L2 · W), where L is the length and W is the width of the tumor, measured by 
external caliper. The tumors were monitored and included in the study when reaching a tumor size 
of ~150 mm3.  
 
2.10 PET imaging and data analysis 
Mice were slowly injected via the tail vein with 200 µL radiolabeled liposomes containing either 
12-13 MBq 64Cu or 2-3 MBq 52Mn. During the scan procedures all mice were kept anaesthetized 
with 3% sevoflurane (Abbott Scandinavia AB, Solna, Sweden) mixed with 35% O2 and 65% N2 and 
placed on a heating pad. Two mice were positioned side-by-side, separated by a 6 mm polystyrene 
block for PET/CT imaging using an Inveon® small animal PET/CT system with CT based PET 
image attenuation (Siemens Medical Systems, Malvern, PA, USA). The protocol included a CT 
scan followed by a PET scan. Acquisition times for PET scans were performed to provide sufficient 
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numbers of counts and ranged from 5 to 15 minutes. Reconstruction of PET scans were performed 
using maximum a posteriori (MAP) reconstruction algorithm (voxel size: 0.815x0.815x0.796 mm; 
resolution (FWHM) 1.2 mm). Imaging time points for both the 64Cu and 52Mn isotope was 40 min, 
2 h, 6.5 h, 16 h, 24 h, and 30 h after injection (all groups). Additionally, three time points were 
imaged for the 52Mn isotope at day 4, 6, and 8 after injection (group 1 and 2). 
Image analysis was performed using commercially available Inveon software 
(Siemens Medical Systems, Malvern, PA, USA). Regions of interest (ROIs) were manually drawn 
based on the co-registered PET/CT images. The following ROIs were constructed; tumors 
(complete volume delineated), liver, spleen, bladder and blood. Blood activity was estimated from a 
constructed ROI covering the ventricles of the heart. ROIs were subsequently segmented to only 
include the voxels displaying above 80% of maximum activity with the original ROI and clearly 
delineated the heart ventricles. For the 52Mn images ROIs were drawn to cover the femoral bone 
and these were subsequently segmented, based on CT, to exclude solid bone and only include 
central located bone-marrow for detection of accumulation of 52Mn. From the obtained uptake 
values all data was calculated as %ID/g for each organ.  
Statistics on in vivo PET data were calculated in PRISM (version 7.02) using Tukey’s 
multiple comparison test with post hoc two-way ANOVA. For tumor data, one-way ANOVA with 
Tukey’s multiple comparison test was performed, due to unequal sample sizes. For late imaging 
points where only the two 52Mn liposome types were available, Student’s t-test (two-tailed, 
unpaired) was used. Plasma half-lives were calculated for all five individual mice and also 
compared by Tukey’s multiple comparison test with post hoc ANOVA in PRISM.   
 
2.11 Well counting  
After sacrificing animals, tumor, spleen, liver, pancreas, and muscle tissue was collected from three 
mice in each group and gamma counted (Wizard Well Counter, Perkin Elmer, US). Mice were 
sacrificed 4 days after injection for 64Cu-surface and 64Cu-remote, and 11 days after injection for 
52Mn-surface and 52Mn-remote. Tissue samples were counted for 1 minute for 52Mn and 10 minutes 
for 64Cu. Results were collected as CPM (counts per minute) and corrected for decay and counting 
efficiency. Final results are presented as %ID/g calculated from CPM values and the weight of the 
specific organ. Well-counting data were compared for each radionuclide by Student’s t-test (two-
tailed, unpaired). 
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Figure 2: Radiolabeling of liposomes with 52Mn. (A+B) Comparison of liposome loading using different 
ionophores,  8HQ, 8HQ-2Cl and 8HQ-2I at internal liposome pH values of 4.0 or 7.8. The loading efficiency 
was determined by size-exclusion chromatography (SEC, A) as well as by radio-TLC (B) at 1 h, 2 h and 3 h. 
SEC and TLC analyses were in addition conducted after a 24 hour EDTA challenge to elucidate the loading 
stability. A control experiment without ionophores was included. (C) Comparison of the loading rate of 
52Mn into liposomes using different ionophore concentrations. The rate was assessed at 2, 10, 20 and 50 
µM 8HQ-Cl using radio-TLC. All remote loading experiments were conducted at 55 oC, 10 mM lipid, 12-15 
MBq 52Mn/ml and 20 µM ionophore (A+B). (D) Surface labeling of 52Mn onto DOTA1% liposomes. The 
loading efficiency was assessed by SEC and radio-TLC after 1 h, 2 h and 3 h for lipid concentrations of 10 
and 20 mM. SEC analysis was in addition conducted after a 24 hour EDTA challenge. All experiments were 
conducted at 55 oC and 12-15 MBq/mL.    
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3. Results and discussion 
 
3.1 Radiochemistry 
We prepared liposomes surface labeled or remote loaded with 52Mn or 64Cu and compared the 
resulting four liposome types head to head in vivo in a murine tumor model to assess the stability of 
the DOTA chelates. As new methodology for 52Mn radiolabeling of liposomes is reported here, 
these procedures were investigated in detail and optimized.  
 
General radiochemistry: Radiolabeling efficiencies were measured by both PD-10 and radio-TLC, 
giving slightly different results. The reason for this is imperfect separation of small molecules and 
liposomes by PD10 resulting in a slight overlap of the large molecule and the small molecule peaks, 
which occurs between 5.5 and 6.0 mL. Since we only considered the elution up to 5.5 mL as 
belonging to the liposomes, the PD-10 results are generally artificially lower than the TLC results, 
as the overlapping region occurs after 5.5 mL. In the preparation of 64Cu-surface for in vivo 
experiments PD-10 analysis only gave 93% labeling efficiency (TLC gave 100%), for which reason 
this preparation was also analyzed on SEC HPLC, giving 98% labeling efficiency. Radio-TLC 
analyses of 64Cu-remote and 52Mn-remote were based on previous observations that encapsulated 
DOTA-radiometal chelates will elute freely on silica if the liposomes containing them are spotted 
and the spot is allowed to dry. DOTA does not react with free 64Cu or 52Mn on silica, which was 
tested by applying free radiometal and DOTA-encapsulating liposomes in the same spot and 
allowing it to dry. In that case, all radioactivity stayed at the origin. This allows determination of 
loading efficiency by radio-TLC. Note that EDTA was added in the analyses of 64Cu-remote and 
52Mn-remote to also elute potential free radiometal (Cu-EDTA Rf: 0.7, Mn-EDTA Rf: 0.4, broad 
peak). 52Mn-surface was analyzed by radio-TLC in a different system, on cellulose eluted with a 
citrate buffer. Here, free 52Mn is complexed by the citrate (Rf = 1.0), making it possible to 
distinguish it from 52Mn bound to liposomes (non-eluting). Note that the ionophore-radiometal 
complexes do not elute in the employed TLC systems.       
 
Remote loading of 52Mn (52Mn-remote): In this method, loading of the radionuclide is facilitated 
by a strong transmembrane cation gradient as previously described for 64Cu [7]. In initial attempts, 
liposomes entrapping DOTA were loaded with 52Mn without the use of ionophores, which resulted 
in a poor loading efficiency (<30% on PD-10 and <20% on TLC, see Control in Fig. 2 A-B). 
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Because of this, the ionophores 2-HQ and 8-HQ were included to assist the diffusion of 52Mn across 
the lipid bilayer. Little increase in loading efficiency was gained by adding 2-HQ (data not shown). 
However, the use of 8-HQ resulted in increased loading (>70% on PD-10, 3 h loading) for 
liposomes entrapping DOTA at pH 7.8 (Fig 2 A-B). In order to push the equilibrium of the 
loading/exchange reaction (Mn(IO)x + DOTA(lip)  MnDOTA(lip) + x IO, where IO is short for 
ionophore) further, two optimization strategies were devised. In one approach, the 52Mn-ionophore 
complex stability was reduced by including chloro (8-HQ-2Cl) or iodo (8-HQ-2I) electron 
withdrawing substituents on the quinolone ring of the ionophore. In the second approach, the 
binding affinity of the entrapped chelator and ionophore was reduced by lowering the pH value and 
hence increasing the protonation of these inside the liposome lumen. For liposomes entrapping 
DOTA at pH 4.0 or pH 7.8, improved loading efficiency (>95% loading on PD-10 and >98% 
loading on Radio-TLC) was obtained when 8-HQ-2Cl was used as ionophore (Fig. 2A-B). Equally 
high loading efficiencies were obtained for liposomes entrapping DOTA at pH 4.0 when using 8-
HQ and 8-HQ-2I as ionophores. 8-HQ-2I was only tested for liposomes entrapping DOTA at pH 
4.0 as its poor solubility in EtOH limited its use. Complete loading (>95%) was reached within the 
first hour in all cases except for 8-HQ at pH 7.8. In the latter case, a gradual increase in loading 
efficiency was observed as a function of time. These results showed that the loading efficiency, and 
thereby the exchange of the radiometal from the ionophore complex to DOTA, could be optimized 
by destabilization of the 52Mn-ionophore complex using electron-withdrawing substituents. Similar 
reduction in the binding affinity of copper with 8-HQ versus 8-HQ-2Cl has previously been 
reported [26] which substantiates the claim of destabilization of the 52Mn-ionophore complex. 
Moreover, a reduction of the pH inside the liposomes from 7.8 to 4.0 resulted in complete loading 
for 8-HQ, 8-HQ-2Cl and 8-HQ-2I.  
Both remote-loaded and surface-labeled liposomes exhibited high stability of the 
radiolabel when exposed to an EDTA challenge for 24 hours. Less than 5% decline in loading 
efficiency (Fig. 2A-B) was observed between the 3- and 24-hour time-point. Hence, unloading of 
52Mn in vivo is highly unlikely as long as the liposomes remain intact in vivo, which they have been 
shown in previous studies to be [3,25]. The high loading efficiencies (>95%) obtained for 52Mn in 
this study compares to previous results obtained for the remote loading of 64Cu [7,27]. In previous 
studies, we tested stealth liposomes remote-loaded with 64Cu-DOTA both with and without 
ionophores against serum, finding that no leakage of the radioactivity occurred [3]. Likewise, the 
stability of the DOTA complexes of 52Mn and 64Cu against serum has been evaluated previously 
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and found to be excellent [15,28]. For these reasons, high serum stability of both surface-labelled 
and remote-loaded liposomes was expected. 
The impact of the ionophore concentration on the loading rate was investigated using 
radio-TLC (Fig. 2C). The loading rate was shown to increase with increasing ionophore 
concentration. The metal ion content of the loading rate assay was estimated to be about 4.3 µM 
metal ions, including 0.27 µM Mn. Thus, addition of 2 µM ionophore represents a small excess 
compared to Mn but is insufficient to chelate the total number of cations present. Hence, by adding 
10-25-fold higher ionophore concentrations, all cations are likely to be chelated by the ionophore 
and the loading completes within 5-30 min (Fig. 2C). The loading rate and optimal amount of 
ionophore thus depends on the metal ion content of the sample and therefore the radionuclide 
purity. Remote loading of 64Cu is described in-depth in previous publications and not discussed here 
[7].  
Based on these findings, a conserved ionophore/lipid ratio of 20µM/10mM was used 
for remote loading 52Mn into the liposomes used for in vivo studies. 
 
Surface labeling of 64Cu and 52Mn: In this method, radiolabeling was facilitated by a high affinity 
chelator (DOTA) which had been covalently bound to a lipid that was incorporated into the 
liposome surface (Figure 1). This method has been described by Seo et al. [18]. For this purpose, 
the lipid conjugate DOTA-DSPE was synthesized, as the DSPE anchor had been previously shown 
to be stably embedded in liposome membranes composed of HSPC, Cholesterol and DSPE-PEG2k 
[18]. Initially, radiolabeling was conducted at 13 MBq 52Mn/mL using 10 mM liposomes, which 
resulted in partial labeling (Fig. 2D). By doubling the lipid concentration, and hence the amount of 
DOTA-DSPE, quantitative radiolabeling (>95%) was obtained within the 3 hour incubation period. 
For 64Cu, complete loading (>94% on SEC and >99.5% on TLC) was obtained for both 10 and 20 
mM liposomes after 1 hour, and the loading efficiency remained high after 2 and 3 hours of 
incubation (data not shown). For both 52Mn and 64Cu, a 24 hour EDTA challenge of the surface 
labeled liposomes resulted in less than 4% decrease in the loading efficiency. The observed loading 
efficiency and stability of the DOTA-DSPE functionalized liposomes were fully comparable with 
remote loaded liposomes for both 52Mn and 64Cu.  
 
3.2  In vivo evaluation 
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All four liposome types were intravenously injected into CT26-tumor bearing mice. In all cases, 
200 µL liposome dispersion (20 mM lipid) was administered, corresponding to 160 µmol lipid/kg. 
This is a 5-fold higher lipid dose than normally used for imaging in our group [7,25,29]. Doses 
within this range may suffer less first pass clearance [30]. Representative PET/CT images of the 
52Mn- and 64Cu-liposome scans at the different time-points are illustrated in Figure 3. Regions-of-
interest were marked and quantified (Figure 4A-E) and compared to post-mortem gamma-counted 
activity levels (Figure 4F). All accumulation values are reported as percent injected dose per gram 
tissue (%ID/g). The comparison of the four liposome types was used to assess the stability of the 
64Cu-DOTA and 52Mn-DOTA chelates. Liposomes represent a unique platform for such in vivo 
analyses as they allow the sequestration of a given radiometal-chelate into two isolated 
compartments, encapsulated or surface-conjugated. The encapsulated remote-loaded chelate is 
completely shielded from interactions with bloodstream components, preventing transchelation of 
free radiometal and enabling immediate reuptake by resident free DOTA in case of release from the 
chelate. On the other hand, the surface-conjugated chelate, DOTA-DSPE, is situated at the lipid 
bilayer interface and is in contact with the bloodstream, making it vulnerable to the conditions that 
might cause instabilities of the chelate during in vivo imaging. Further, since both types are long-
circulating, this setup allows their comparison and analysis of stability differences over hours to 
days, providing a scenario that mirrors a realistic preclinical/clinical setting.  
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Figure 3: Coronal and transverse PET/CT images Balb/C mice carrying CT26 tumors injected with 
surface or remote loaded liposomes. Images recorded after 40 min, 6.5 hours, 16 hours, 30 hours, 4 
days and 8 days are shown for 52Mn-labelled liposomes and after 40 min, 6.5 hours, 16 hours and 
30 hours for 64Cu-labelled liposomes. Tumors are highlighted in the transverse images by a dashed 
circle. 
 
 
Figure 4: Biodistribution of remote and surface labeled liposomes based on PET imaging (A-E) or 
organ well counting (F-G). The accumulation (%ID/g) in blood (A), tumor (B), liver (C), spleen (D) 
and urinary bladder (E) is shown as a function of time for surface or remote labeled liposomes for 
both 64Cu and 52Mn. (F-G) Biodistribution of remote and surface labeled liposomes based on organ 
well counting. The animals were sacrificed 4 days and 11 days post injection for the 64Cu and 52Mn 
liposome groups respectively. The results are reported as mean and SEM (A-E n = 5, F-G n = 3).  
 
 
Analysis of chelate stabilities: Radioactivity levels by PET and ex vivo well-counting for all 
analyzed organs are seen in figure 4. Overall, the four liposome types were observed to follow 
similar clearance from the blood pool, with little difference between them (figure 4A, for all p-
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values, see Supplementary Materials S3). The most consistent difference was between 52Mn-
surface and the two remote-loaded formulations, where 52Mn-surface showed significantly lower 
blood values (p < 0.01) at 6.5, 16, 24 and 30 h compared with 52Mn-remote. A similar pattern of 
reduced blood levels was observed for 64Cu-surface compared to 64Cu-remote (6.5 hours: p < 
0.0001, 16 hours: p = 0.03 and 24 hours: p = 0.004). The two remote-loaded formulations, which 
were expected to have the most stable radiolabels due to their shielding from the surroundings, 
exhibited largely identical blood values, demonstrating the stability of these radiolabels. No clear 
biphasic elimination pattern could be determined for the liposomes. With a monophasic exponential 
fit from 0 – 30 h, plasma half-lives were determined to be 20.3 ± 1.2 h (64Cu-remote, r2 = 0.99 ± 
0.00), 17.2 ± 2.9 h (64Cu-surface, r2 = 0.99 ± 0.01), 21.3 ± 2.4 h (52Mn-remote, r2 = 0.96 ± 0.03) and 
14.4 ± 1.2 h (52Mn-surface, r2 = 0.96 ± 0.01). These half-lives are similar or slightly longer than 
what is typically observed for stealth liposomes in murine models by our group [7,8,25,29]. 52Mn-
surface was found to have a significantly shorter bloodstream half-life (14.4 h) than the other three 
liposome types, differing significantly from 64Cu-remote (p = 0.0019) and 52Mn-remote (p = 
0.0004), but not from 64Cu-surface (p = 0.19). In summary, the in vivo PET blood data showed 
generally faster elimination of the radiolabel for the two surface-labeled types, with resulting lower 
blood values and half-lives. This was more pronounced for 52Mn-surface than for 64Cu-surface. 
Accordingly, the blood data suggest that the 52Mn-DOTA chelate may be unstable when exposed to 
plasma components. The possible mechanisms of this indicated instability are currently unknown 
and will require further studies. From the obtained data, it is inconclusive whether this also applies 
to 64Cu-DOTA. 
 For the remaining organs, no clearly interpretable patterns were found, except for the 
urinary bladder. The radioactivity in the urine was observed to be markedly higher for 64Cu-remote 
and 52Mn-remote in the first 5 hours of imaging. Since chelates of radionuclides are known to 
undergo renal excretion [25], this could stem from limited liposomal rupture and release of cargo as 
a result of opsonization in the first hours after injection [31]. With chelates bound to lipid 
molecules, as is the case for the two surface-labeled types, such renal excretion would be unlikely. 
High initial urinary excretion of free radionuclide chelates inside liposomes has been previously 
observed [32]. In addition, significant difference was found between 64Cu-surface and 52Mn-surface 
at all time points beyond 40 min, with 52Mn-surface showing higher urinary excretion. This may 
also hint at limited in vivo stability of the 52Mn-DOTA. One should note that quantitative evaluation 
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of renal excretion by PET imaging has limited validity without correction in regards to urinary 
output etc. but this was not feasible in our current setup.           
The ex vivo data for 64Cu-remote and 64Cu-surface (figure 4F) were tested against 
each other with no significant differences found, except for pancreas (p = 0.03). Specific pancreatic 
uptake of free 64Cu has to our knowledge not been previously reported. For the 52Mn-liposomes, no 
significant differences were found. Accordingly, the well-counting data show similar biodistribution 
of surface versus remote loading for both radionuclides. This supports that the surface DOTA 
chelates are sufficiently stable for quantitative imaging with 64Cu. The high pancreatic uptake of 
52Mn at 11 d (Figure 4F) indicates that 52Mn may be extracted from DOTA after metabolism of the 
liposomes, and end up in the pancreas, a known sink organ for free 52Mn [14]. This also hints at a 
somewhat compromised in vivo stability of 52Mn-DOTA.         
In both cases of surface-labeling, there is the theoretical possibility of migration of the 
radiolabeled lipids to other endogenous sites. This however, is not expected to occur for chelator-
functionalized lipids with double C18 anchors [18]. In addition, the slightly faster clearance of the 
surface-labeled liposomes could be caused by increased uptake by immune cells due to the presence 
of charged DOTA on the surface. For this reason we measured complement activation of the 
DOTA1% liposomes (DOTA on surface) and compared with LIP780 (DOTA in aqueous 
compartment). For full results, see Supplementary Materials S4. Overall, a 2.1 and 1.6-fold 
increase in SC5b-9 compared to background was observed for the DOTA1% and LIP780 
formulation respectively. This is a less pronounced activation profile compared to results published 
by Wibroe et al. that reported a 2-40 fold increase in SC5b-9 levels for a range of liposomal 
doxorubicin formulations [33]. Accordingly, surface-functionalized DOTA causes slightly higher 
complement activation, but whether this limited effect could be a factor in the enhanced clearance is 
currently unknown.  
In consequence, our results indicate that 52Mn-DOTA may not be a suitable chelate for 
preclinical in vivo imaging. In opposition to this, Graves et al. reported limited uptake in the 
pancreas (2.5 %ID/g) during long-term imaging (5 days) with exposed 52Mn-DOTA [14], and our 
own group previously found excellent serum stability in vitro [15]. The observed high serum 
stability of the chelate indicates that competition from endogenous metals in the blood does not 
displace 52Mn from DOTA to a significant degree. Accordingly, fFurther studies should fully clarify 
the status of 52Mn-DOTA. 
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Whether or not DOTA should continue to be the chelator of choice for 64Cu in 
preclinical and clinical nuclear imaging is a source of much debate. DOTA is commercially 
available in multiple bifunctional forms, and chelates 64Cu at room temperature and significant 
levels of knowledge on it use exist. However, several studies have reported transchelation of 64Cu in 
vivo as well as reduced PET signal contrast between target and non-target organs when compared to 
other chelators [34,35]. This is in contrast to a generally reported high serum stability of the 64Cu-
DOTA chelate [36,37]. It has been suggested that the facile reduction of Cu(II) to Cu(I), with 
consequent dechelation, may be implicated in the in vivo instability [38]. Since Mn(II) is fairly 
easily converted to Mn(IV), it may be speculated that redox processes also play a role in the 
observed instability of 52Mn-DOTA. In spite of the apparent in vivo  instability of 64Cu-DOTA, it is 
successfully employed in the clinic with good image quality [39,40]. In this study we found some 
evidence that a 64Cu-DOTA complex conjugated to the surface of liposomes fared differently than a 
64Cu-DOTA complex shielded within such liposomes, which may indicate compromised stability of 
the complex. However, the effect was generally not significant. Although free 64Cu is known to 
accumulate in liver and some tumors, it is rapidly removed from the bloodstream upon injection and 
does not accumulate significantly in spleen [15,41]. Our results showed no clear pattern of 
significant difference between the blood stream circulation and splenic uptake of 64Cu-surface and 
64Cu-remote, indicating no or little release of free 64Cu. Overall, our results do not clearly show 
whether 64Cu-DOTA is stable in vivo or not, but no clear evidence of in vivo instability was 
observed. Although this chelate may be demonstrated to be less stable than with other chelators, 
such as CB-TETA, NOTA, DIAMSAR and NODAGA, our results support that this is unlikely to 
have any substantial effect in a practical in vivo setting.  
 
Post-distribution trafficking of 52Mn-radiolabels: Due to the long physical half-life of 52Mn, 
52Mn-remote and 52Mn-surface could be imaged beyond the usual 2-3 days of liposome PET 
imaging that we typically perform. At the 4, 6 and 8 day time points, the blood radioactivities were 
found to have stabilized around 2-4 %ID/g. This indicates that some transport of 52Mn into the 
bloodstream may occur. This is supported by Graves et al. who found the blood concentration to be 
around 4%ID/g at the 96 hour time-point after injection of free 52Mn [14]. We observed an average 
of 3.3 ± 1.0 %ID/g at this time. We found no significant difference between the two types at these 
late time-points. 
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The tumor accumulation of the two 52Mn-labeled types increased until 30 hours 
followed by a drop in values at later time-points. This demonstrated that radionuclides that are taken 
up in tumor tissue can undergo elimination from the tumor, and that this elimination occurs 
independently of whether the radionuclide-chelator complex is free or conjugated to a lipid. This 
was also recently observed by Seo et al. for liposomes surface-labeled with 89Zr [11]. 52Mn-remote 
exhibited a tumor clearance half-life of 80 ± 11 h (r2 = 0.98 ± 0.03), and 52Mn-surface a half-life of 
106 ± 10 h (r2 = 1.00 ± 0.00). These were calculated by exponential regression on the 4, 6 and 8 day 
time-points. The clearance half-lives were significantly different (p = 0.027), indicating that the 
position and chemical form of the radiolabel influences clearance from tumor tissue. This supports 
the findings of Seo et al. where the length of the linker (buried versus exposed chelate) significantly 
affected the excretion from the tumor [11]. The faster clearance of 52Mn-remote may be caused by 
destruction of the liposomes after cellular uptake, followed by easier washout of the highly 
hydrophilic 52Mn-DOTA chelate. Long-term imaging of the two 52Mn liposome types showed 
elimination from the liver and spleen after 30 hours at similar rates for the two. 
With the current interest in using radiolabeled liposomes as theranostic PET 
radiotracers for predicting the presence of the EPR effect in a clinical setting in human subjects, the 
choice of radionuclide becomes relevant. Due to the longer time-span of biodistribution in humans, 
longer-lived radionuclides may be preferable. In this case, a reduced patient dose is received if the 
accumulated radioactivity is subsequently eliminated, especially from highly accumulating organs 
as liver and spleen. These results show that this may be the case. In order to showcase the 
dosimetric significance of elimination from organs and the general use of long-lived PET 
radionuclides dosimetry calculations were made. These are presented in supplementary materials 
S5, and showed that the received dose from using 52Mn or 64Cu depends heavily on the time of 
image recording. With imaging times after around 69 hours post-injection, 52Mn was found to have 
favorable dosimetry.      
 
General biodistribution: The highest observed tumor accumulation values for all four liposome 
types were around 4%ID/g, with limited significant difference at all time-points between the 
groups. For 52Mn-remote was observed a tumor accumulation value of around 6.4 ± 1.0 %ID/g at 30 
h, and a significantly higher level than the other three groups from 6.5 to 30 h. The reason for this 
was that two tumors in the 52Mn-remote group exhibited higher uptake of the radiolabeled 
liposomes. We speculate that this may have been due to their larger size which corresponded with 
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higher accumulation per mass (%ID/g) (see Supplementary Materials S6 for discussion). Previous 
studies have reported higher liposome %ID/g in smaller tumors as compared to larger tumors, 
which is in disagreement with our data [8,32]. Where we used the tumor cell-line CT26 (colon 
carcinoma), other studies have used NCI-H727 (neuroendocrine tumor, [8]) or KB (squamous cell 
cancer, [32]), so tumor type may have some influence. Syngenic cancer models tend to have much 
less intratumoral necrosis compared to xenografts, especially for larger tumors [42], which may 
explain the higher mean uptake per mass in smaller tumors reported in some studies. Accordingly, 
we do not consider the higher observed tumor uptake of 52Mn-remote to be a reflection of liposomal 
properties. The peak tumor accumulations reached by all four groups are similar to previously 
reported values for liposomes in murine tumor xenograft models [11,25,29]. A discussion of tumor 
accumulation data can be found in Supplementary Materials S6.  
Liver accumulation was similar for all four liposomes types, with high initial values 
around 25 %ID/g, increasing until 30 hours, reaching values around 30-45 %ID/g. These values 
were higher than typically reported data for liposomes in murine models, potentially due to the mice 
strain used in the study at hand. Further studies are needed to decipher the mechanisms underlying 
this observation, which is beyond the scope of this paper. Few clear patterns of significant 
difference between the four liposome types were identified, but 52Mn-surface exhibited higher liver 
accumulation than the other types and was different from 64Cu-remote (lowest liver accumulation) 
at 6.5, 24 and 30 hours (p < 0.01 in all cases). This may be a result of both release of 52Mn from the 
DOTA-DSPE chelate with subsequent liver accumulation, or because of immune cell interactions 
with the chemically distinct surface DOTA moieties. However, no such pattern was observed for 
64Cu-surface. Free 52Mn has been reported to accumulate in liver [14]. Spleen accumulation was 
characterized by high initial accumulation of the two 52Mn liposomes with higher activity of 52Mn-
remote compared to the other liposome types at almost all time-points. A clear pattern of 
significantly higher splenic accumulation was found for 52Mn-remote compared to 64Cu-remote at 
all time-points (p < 0.05). However, there is no clear reason for this, as these two liposome types 
should have identical surface characteristics.  
In addition to the %ID/g values reported here, absolute accumulation data (%ID) can 
be found in Supplementary materials S7. In this section the total body radioactivity as a function 
of time is also provided (Fig. S3E+F). The total radioactivity accounted for was around 100% at the 
start of scans and was eliminated with a half-life of about 50 hours, largely independent of liposome 
type. 
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The ex vivo accumulation data for tumor, spleen and liver (Figure 4F) mirrored the 
values obtained by PET imaging, with somewhat lower values for well-counting of 52Mn-
liposomes, due to the passing of an additional three days after the last PET time-point (8 days). 
Pancreas was included since free 52Mn has been reported to accumulate strongly in this organ [14], 
while free 64Cu is known to accumulate in liver [20,41].  
 
 
4. Conclusion 
We have successfully developed an ionophore assisted method for remote loading of stealth 
liposomes with the long-lived PET isotope 52Mn. Optimal loading conditions (>95% loading 
efficiency) were achieved either by reduction of intra-lumen pH of the liposomes or by use of 
chloro- or iodo-substituted analogues of the ionophore, 8-hydroxyquinoline. In addition, protocols 
for surface labelling of liposomes with 64Cu or 52Mn were developed. 
Liposomes remote-loaded or surface-labeled with 64Cu or 52Mn were compared head-
to-head in an in vivo biodistribution study in Balb/C mice, in order to investigate the in vivo 
stability of the 64Cu-DOTA and 52Mn-DOTA chelates. The biodistribution of all four liposome 
types was similar overall, but with remote loaded liposomes circulating with longer plasma half-
lives than their surface labeled counterparts. 52Mn-surface exhibited a significantly shorter plasma 
half-life than 52Mn-remote (14.4 ± 1.2 h versus 21.3 ± 2.4 h), showing that 52Mn-DOTA may be 
unstable when exposed to the bloodstream and potentially unsuitable for use in quantitative studies. 
The cause of this in vivo instability is currently unknown. 64Cu-surface also showed faster clearance 
from the bloodstream than 64Cu-remote, but the difference was not significant (17.2 ± 2.9 h versus 
20.3 ± 1.2 h). Accordingly, our results support that 64Cu-DOTA is suitable for both qualitative and 
quantitative imaging. 
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